Tamoxifen resistance in breast cancer elucidating mechanisms

Drugs

Volumn 61, Issue 12, 2001, Pages 1721-1733

  Dorssers, L C J ^a   Van Der Flier, S ^a   Brinkman, A ^a   Van Agthoven, T ^a   Veldscholte, J ^a   Berns, E M J J ^a   Klijn, J G M ^a   Beex, L V A M ^b   Foekens, J A ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GENE PRODUCT; HORMONE; PROTEIN BCAR; PROTEIN P130; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; DISEASE ASSOCIATION; EPITHELIUM CELL; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TUMOR CELL;

EID: 0034770128     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00004     Document Type: Review

References (161)

1. Endogenous hormones and breast cancer risk
2. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
3. Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis
4. Cellular basis of breast cancer susceptibility
5. Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer. A contribution to the biology and natural history of carcinoma of the female breast
6. The nuclear receptor superfamily: The second decade
7. Steroid hormone receptors: Many actors in search of a plot
8. Nuclear receptor coregulators: Cellular and molecular biology
9. Nuclear hormone receptor coregulators in action: Diversity for shared tasks
10. Molecular chaperone interactions with steroid receptors: An update
11. Cloning of a novel receptor expressed in rat prostate and ovary
12. ERβ: Identification and characterization of a novel human estrogen receptor
13. Expression of estrogen receptor β messenger RNA variant in breast cancer
14. Coexpression of estrogen receptor alpha and beta: Poor prognostic factors in human breast cancer?
15. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients
16. Prognostic significance of oestrogen receptor beta in breast cancer
17. Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR
18. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer
19. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer
20. The hallmarks of cancer
21. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases
22. Progestin action and progesterone receptor structure in human breast cancer: A review
23. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis
24. Basic guide to the mechanisms of antiestrogen action
25. Estrogen receptors in breast cancer
26. Molecular basis of agonism and antagonism in the oestrogen receptor
27. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
28. Endocrine pharmacology of antiestrogens as antitumor agents
29. Tamoxifen for early breast cancer: An overview of the randomised trials
30. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
31. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
32. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
33. Tamoxifen, raloxifene, and the prevention of breast cancer
34. Reducing the risk of breast cancer
35. Effects of anti-estrogens on bone in castrated and intact female rats
36. Species-specific pharmacology of antiestrogens: Role of metabolism
37. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
38. Contrasting actions of tamoxifen on endomethal and breast tumor growth in the athymic mouse
39. Antiestrogens - Tamoxifen, SERMs and beyond
40. Selective estrogen receptor modulators: Structure, function, and clinical use
41. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
42. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
43. Use of tamoxifen for breast cancer: Twenty-eight years later
44. Assessment of response to therapy in advanced breast cancer
45. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
46. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
47. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer
48. Prognostic and predictive factors in breast cancer
49. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
50. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
51. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
52. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
53. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
54. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
55. Complete sequencing of TP53 predicts poor response to systemic treatment of advanced breast cancer
56. Thymidine kinase and thymidylate synthetase in advanced breast cancer: Response to tamoxifen and chemotherapy
57. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
58. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
59. Oestrogen receptor: A stable phenotype in breast cancer
60. Comparison of estrogen receptor DNA binding in untreated and acquired anti-estrogen-resistant human breast tumors
61. Recent advances in endocrine therapy of breast cancer
62. Use of aromatase inhibitors in breast carcinoma
63. New hormonal therapies for breast cancer
64. Receptors, growth factors and steroid insensitivity of tumours
65. Towards a molecular basis for tamoxifen resistance in breast cancer
66. Mechanisms of hormone resistance in breast cancer
67. Molecular mechanisms of antiestrogen action in breast cancer
68. Mechanisms of tamoxifen resistance
69. Hormone resistance, invasiveness, and metastatic potential in breast cancer
70. Molecular markers of resistance to endocrine treatment of breast cancer
71. Cross-resistance and molecular mechanisms in antiestrogen resistance
72. Anti-estrogens: Mechanisms of action and resistance in breast cancer
73. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
74. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use
75. Drug resistance to tamoxifen during breast cancer therapy
76. Tamoxifen in the treatment of breast cancer
77. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites
78. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
79. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
80. Endocrine resistance in advanced breast cancer
81. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
82. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
83. Steroid/thyroid receptor-like proteins with oncogenic potential: A review
84. Estrogen receptor mutations in tamoxifen-resistant breast cancer
85. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer
86. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
87. Variant human breast tumor estrogen receptor with constitutive transcriptional activity
88. Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells
89. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer
90. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer
91. Oestrogen receptor mutants and variants in breast cancer
92. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas
93. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer
94. Expression of estrogen receptor beta 1, beta2, and beta5 messenger RNAs in human breast tissue
95. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions
96. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions
97. Antiestrogen action and growth factor regulation
98. Growth factors in breast cancer
99. Oestrogen growth factor cross-talk in breast carcinoma: A specific target for novel antioestrogens
100. Transforming growth factor-β in breast cancer: A working hypothesis
101. Genetic mechanisms involved in progression to hormone independence of human breast cancer
102. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells
103. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer
104. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance
105. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
106. Linking gene expression patterns to therapeutic groups in breast cancer
107. Transfection of v-RasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorgenicity
108. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression
109. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
110. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
111. The significance of heregulin in breast cancer tumor progression and drug resistance
112. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice
113. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice
114. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor
115. Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice
116. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle
117. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis
118. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
119. Overexpressed IGF-1 receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells
120. Expression of CYR61, a ligand for integrin αVβ3, modulates breast cancer progression
121. Constitutive activation of the serine/threonine kinase AKT confers tamoxifen resistance and hormonal autonomy in ERα positive breast cancer cells
122. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations
123. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
124. Antiestrogen resistance in ER positive breast cancer cells
125. cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo
126. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site
127. Retroviruses
128. Retroviral mutagenesis of cellular oncogenes: A review with insights into the mechanisms of insertional activation
129. Retroviral insertional mutagenesis as a strategy to identify cancer genes
130. Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells
131. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
132. Identification of the breast cancer susceptibility gene BRCA2
133. BCAR1, a human homologue of the adapter protein p 130Cas and antiestrogen resistance in breast cancer cells
134. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner
135. Involvement of pl30Cas and pl05HEF1, a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells
136. Integrin signalling: A new cas(t) of characters enters the stage
137. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells
138. Bcar1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment
139. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas
140. Mammary epithelial stem cells: Our current understanding
141. Three division-competent, structurally-distinct cell populations contribute to murine mammary epithelial renewal
142. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland
143. The cytokeratin profile of medullary carcinoma of the breast
144. Impact of progesterone receptor on cell-fate decisions during mammary gland development
145. The transition from hyperplasia to invasive carcinoma of the breast
146. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry
147. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
148. Dissociation between steroid receptor expression and cell proliferation in the human breast
149. Oestrogen receptor expression in the normal and pre-cancerous breast
150. Estrogen receptor-positive proliferating cells in the normal and precancerous breast
151. Pathological studies of apoptosis in the normal breast
152. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
153. Clinical studies of apoptosis and proliferation in breast cancer
154. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
155. Breast cancer: Relevance of estrogen receptor determination at relapse
156. Expression profiling using cDNA microarrays
157. Exploring the new world of the genome with DNA microarrays
158. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
159. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
160. Molecular classification of cutaneous malignant melanoma by gene expression profiling
161. Molecular portraits of human breast tumours